Literature DB >> 11574568

Nonisotopic detection of human papillomavirus DNA in clinical specimens using a consensus PCR and a generic probe mix in an enzyme-linked immunosorbent assay format.

J R Kornegay1, A P Shepard, C Hankins, E Franco, N Lapointe, H Richardson, F Coutleé.   

Abstract

We assessed the value of a new digoxigenin (DIG)-labeled generic probe mix in a PCR-enzyme-linked immunosorbent assay format to screen for the presence of human papillomavirus (HPV) DNA amplified from clinical specimens. After screening with this new generic assay is performed, HPV DNA-positive samples can be directly genotyped using a reverse blotting method with product from the same PCR amplification. DNA from 287 genital specimens was amplified via PCR using biotin-labeled consensus primers directed to the L1 gene. HPV amplicons were captured on a streptavidin-coated microwell plate (MWP) and detected with a DIG-labeled HPV generic probe mix consisting of nested L1 fragments from types 11, 16, 18, and 51. Coamplification and detection of human DNA with biotinylated beta-globin primers served as a control for both sample adequacy and PCR amplification. All specimens were genotyped using a reverse line blot assay (13). Results for the generic assay using MWPs and a DIG-labeled HPV generic probe mix (DIG-MWP generic probe assay) were compared with results from a previous analysis using dot blots with a radiolabeled nested generic probe mix and type-specific probes for genotyping. The DIG-MWP generic probe assay resulted in high intralaboratory concordance in genotyping results (88% versus 73% agreement using traditional methods). There were 207 HPV-positive results using the DIG-MWP method and 196 positives using the radiolabeled generic probe technique, suggesting slightly improved sensitivity. Only one sample failed to test positive with the DIG-MWP generic probe assay in spite of a positive genotyping result. Concordance between the two laboratories was nearly 87%. Approximately 6% of samples that were positive or borderline when tested with the DIG-MWP generic probe assay were not detected with the HPV type-specific panel, perhaps representing very rare or novel HPV types. This new method is easier to perform than traditional generic probe techniques and uses more objective interpretation criteria, making it useful in studies of HPV natural history.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574568      PMCID: PMC88384          DOI: 10.1128/JCM.39.10.3530-3536.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

3.  Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus.

Authors:  F Coutlée; A M Trottier; G Ghattas; R Leduc; E Toma; G Sanche; I Rodrigues; B Turmel; G Allaire; P Ghadirian
Journal:  Sex Transm Dis       Date:  1997-01       Impact factor: 2.830

4.  Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Authors:  P E Gravitt; C L Peyton; R J Apple; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group.

Authors:  F Coutlée; C Hankins; N Lapointe
Journal:  J Med Virol       Date:  1997-01       Impact factor: 2.327

6.  Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. The Canadian Women's HIV study group.

Authors:  F Coutlée; P Gravitt; H Richardson; C Hankins; E Franco; N Lapointe; H Voyer
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

7.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.

Authors:  E L Franco; L L Villa; J P Sobrinho; J M Prado; M C Rousseau; M Désy; T E Rohan
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

8.  Persistence of type-specific human papillomavirus infection among cytologically normal women.

Authors:  A Hildesheim; M H Schiffman; P E Gravitt; A G Glass; C E Greer; T Zhang; D R Scott; B B Rush; P Lawler; M E Sherman
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

9.  Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group.

Authors:  C Hankins; F Coutlée; N Lapointe; P Simard; T Tran; J Samson; L Hum
Journal:  CMAJ       Date:  1999-01-26       Impact factor: 8.262

10.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

View more
  7 in total

1.  Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test.

Authors:  François Coutlée; Danielle Rouleau; Patrick Petignat; Georges Ghattas; Janet R Kornegay; Peter Schlag; Sean Boyle; Catherine Hankins; Sylvie Vézina; Pierre Coté; John Macleod; Hélène Voyer; Pierre Forest; Sharon Walmsley; Eduardo Franco
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Generic microtiter plate assay for triaging clinical specimens prior to genotyping of human papillomavirus DNA via consensus PCR.

Authors:  Véronique Legault; Ann Burchell; Patricia Goggin; Belinda Nicolau; Paul Brassard; Julie Guenoun; Pierre Forest; Marie-Hélène Mayrand; Eduardo Luis Franco; Francois Coutlée
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

3.  International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement.

Authors:  Janet R Kornegay; Michel Roger; Philip O Davies; Amanda P Shepard; Nayana A Guerrero; Belen Lloveras; Darren Evans; François Coutlée
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Facile, comprehensive, high-throughput genotyping of human genital papillomaviruses using spectrally addressable liquid bead microarrays.

Authors:  Jan Wallace; Bruce A Woda; German Pihan
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

5.  Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test.

Authors:  Dennis van Hamont; Maaike A P C van Ham; Judith M J E Bakkers; Leon F A G Massuger; Willem J G Melchers
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

6.  Detection of human papillomavirus DNA in cervical samples: analysis of the new PGMY-PCR compared to the hybrid capture II and MY-PCR assays and a two-step nested PCR assay.

Authors:  Lucia Giovannelli; Anna Lama; Giuseppina Capra; Viviana Giordano; Pietro Aricò; Pietro Ammatuna
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

7.  Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients.

Authors:  K-U Petry; S Menton; M Menton; F van Loenen-Frosch; H de Carvalho Gomes; B Holz; B Schopp; S Garbrecht-Buettner; P Davies; G Boehmer; E van den Akker; T Iftner
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.